Prescription ·Strong evidence ·Reviewed May 2026
Cefuroxime is a second-generation cephalosporin beta-lactam antibiotic used to treat a range of bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and early Lyme disease. It is available as an oral prodrug (cefuroxime axetil) and as an intravenous or intramuscular salt (cefuroxime sodium). Compared with first-generation agents, it offers improved activity against many gram-negative organisms while retaining useful gram-positive coverage and greater stability against many beta-lactamases.
The bottom line
Evidence rating strong. Most-documented uses: community-acquired respiratory infections (acute bacterial sinusitis, acute bronchitis exacerbations, pharyngitis/tonsillitis), uncomplicated urinary tract infections, skin and soft tissue infections. 3 sources indexed (1992–2019), with 5 interaction records on file.
Core mechanism
Cefuroxime is a bactericidal beta-lactam that binds to and inhibits penicillin-binding proteins (PBPs) in the bacterial cell wall. By acetylating the active site of these transpeptidase enzymes, it blocks the cross-linking of peptidoglycan strands required for cell wall synthesis and integrity. This leads to weakened cell walls, activation of autolytic enzymes, and ultimately osmotic lysis and death of dividing bacteria. Its second-generation structure confers relative resistance to hydrolysis by many bacterial beta-lactamases, broadening its activity against gram-negative species such as Haemophilus influenzae and Moraxella catarrhalis.2,1
Oral cefuroxime axetil absorption is enhanced when taken with food, which increases bioavailability; the tablet should be taken after a meal. The intravenous and intramuscular forms bypass gastrointestinal absorption entirely. Tablets should not be crushed because of a persistent bitter taste; the oral suspension must be taken with food.3
Nutrients this medication can lower over time, and what to replace.
Broad-spectrum antibiotic suppression of vitamin K-producing colonic bacteria reduces the supply of menaquinones (vitamin K2). Unlike cephalosporins bearing an N-methylthiotetrazole (NMTT) side chain (e.g., cefamandole, cefoperazone), cefuroxime lacks this group and does not directly inhibit the vitamin K epoxide reductase / hepatic gamma-carboxylation pathway, so any hypoprothrombinemia is generally mild and largely confined to patients with poor dietary vitamin K intake, malnutrition, prolonged therapy, or concurrent anticoagulant use.
Cefuroxime can suppress or kill bacterial probiotic organisms if taken at the same time, although selected probiotics may lower antibiotic-associated diarrhea risk.
Recommendation: Separate probiotic doses from the antibiotic by at least 2 hours when feasible; avoid probiotic use in severely immunocompromised patients or patients with central lines unless clinician-directed.
Prolonged Cefuroxime therapy can contribute to reduced vitamin K status in susceptible patients by altering gut flora, with higher concern in poor intake, malabsorption, liver disease, or warfarin use.
Recommendation: Do not self-treat bleeding or INR changes. Monitor for bruising or bleeding and coordinate vitamin K or anticoagulant changes with the prescriber.
Oral iron salts can form insoluble chelates with cephalosporin antibiotics and may also raise gastric pH, both of which can reduce the absorption and serum concentrations of cefuroxime axetil. Cefuroxime axetil absorption is favored by an acidic environment and by being taken with food; concomitant polyvalent cations and acid-altering products may blunt its bioavailability.
Recommendation: Separate oral iron from cefuroxime axetil by at least 2 to 3 hours, taking the antibiotic with food as directed. Do not stop a prescribed antibiotic; instead stagger the iron dose to preserve antibiotic efficacy.
Calcium-containing supplements and antacids can chelate cefuroxime and raise gastric pH. Because cefuroxime axetil relies on an acidic stomach environment for optimal dissolution and absorption, co-administration with calcium or calcium-containing antacids may reduce the antibiotic's absorption.
Recommendation: Take calcium supplements and calcium-containing antacids at least 2 hours apart from cefuroxime axetil. Continue taking the antibiotic with food per the prescription.
Oral zinc, a divalent cation, can chelate cephalosporins and reduce their gastrointestinal absorption. Although best characterized for quinolone and tetracycline antibiotics, the same cation-chelation principle can theoretically lower cefuroxime axetil absorption when taken together.
Recommendation: Separate zinc supplements from cefuroxime axetil by at least 2 hours. Take the antibiotic with food as prescribed and stagger zinc rather than discontinuing it.
Numbered references. Citations throughout the page link here.
Cefuroxime axetil produced clinical outcomes comparable to doxycycline in patients with early Lyme disease.
Approved labeling describes mechanism, indications (including acute bacterial maxillary sinusitis, pharyngitis/tonsillitis, uncomplicated UTI, early Lyme disease), dosing, and adverse effects for oral cefuroxime axetil.
Parenteral cefuroxime is indicated for lower respiratory, urinary, skin, bone/joint, gonococcal, and septicemic infections and for perioperative prophylaxis, with renal dose adjustment.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
